Clinical trial NCT04752371: A Study to Evaluate Camoteskimab in Participants With Still's Disease
Official title: A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Adult Onset Still's Disease
Keywords: Adult Onset Still's Disease
AEVI-007
Camoteskimab
IL-18
sJIA
Lead sponsor: Apollo Therapeutics Ltd
Sponsor class: INDUSTRY
First posted: 2021-02-12
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.


Eligibility criteria: Inclusion Criteria:

1. Subject is 18 to 75 years of age (inclusive) at the time of consent. The date of signature of the informed consent is defined as the beginning of the Screening Period. This inclusion criterion will only be assessed at the Screening Visit (Visit 1).
2. Subject has been diagnosed with AOSD based on classification criteria (according to Yamaguchi et al, 1992) defined as having 5 or more of the following criteria, 2 of which are major:

   a. Major Criteria i. Fever \>39°C, lasting 1 week or longer ii. Arthralgia or arthritis, lasting 2 weeks or longer iii. Typical rash iv. Leukocytes \>10,000 mm3 with \>80% polymorphonuclear cells b. Minor Criteria i. Sore throat ii. Recent development of significant lymphadenopathy iii. Hepatomegaly or splenomegaly iv. Abnormal liver function tests v. Negative tests for antinuclear antibody and rheumatoid factor
3. Subject has reported a recurring fever \>38°C, consistent with active disease, within the last 5 days of the Screening and Baseline Visits.
4. If undergoing treatment with non-steroidal anti-inflammatory drugs (NSAID), subject is on a stable dose for at least 48 hours prior to the Baseline Visit (Visit 2).
5. If undergoing treatment with glucocorticoids, subject is on a stable dose for at least 48 hours prior to the Baseline Visit (Visit 2).
6. If undergoing treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs), subject is on a stable dose for at least 4 weeks prior to the Baseline Visit (Visit 2).
7. For subjects who have received treatment with biological DMARDs, subject has the required washout (normalization) period prior to the Baseline Visit (Visit 2).

   The washout (normalization) period for biological DMARDs is as follows:
   1. Anakinra - 1 week
   2. Etanercept, rilonacept - 4 weeks
   3. Adalimumab, certolizumab, infliximab, golimumab, abatacept, tocilizumab and canakinumab - 8 weeks
   4. Rituximab - 36 weeks
8. Non-pregnant female subjects of childbearing potential who are heterosexually active and non-sterile male subjects with female sexual partners of childbearing potential agree to use a highly effective method of contraception during treatment and for 25 weeks following the last dose of investigational product. A highly effective method of birth control is defined as one that results in a low failure rate (ie, \<1% per year) when used consistently and correctly, such as oral/injectable/inserted/implanted/transdermal contraceptives, intrauterine hormone-releasing system or intrauterine device (IUD), or sexual abstinence. Contraception is not required where at least 6 weeks has passed since sterilization, defined as females having undergone one of the following surgeries: hysterectomy, bilateral tubal ligation or occlusion, bilateral oophorectomy, or bilateral salpingectomy; and males who are vasectomized. Contraception is also not required where females are postmenopausal (defined as 12 consecutive months of spontaneous amenorrhea and age ≥51 years). Females of reproductive potential must have a negative pregnancy test as part of the screening/baseline assessment.
9. Subject has provided written informed consent for this study.
10. Subject is willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is, in the opinion of the investigator, mentally or legally incapacitated, or has significant emotional problems at the time of the Screening Visit (Visit 1) that could interfere with the subject's participation or cooperation with the conduct of study evaluations
2. Subject has a chronic severe or uncontrolled medical disorder that might confound the results of safety assessments conducted in the study in the opinion of the Investigator or Medical Monitor.
3. Subject has another serious chronic-inflammatory disease.
4. Subject has a relevant, active infection or another disease, which entails a tendency towards infection.
5. Subject has active macrophage activation syndrome.
6. Subject has a history of unresolved latent tuberculosis.
7. Subject has the following abnormal values:

   1. Serum creatinine concentration \>1.5 mg/dl.
   2. Hemoglobin ≤ 10 g/dl, neutrophils ≤1,500/μl and/or thrombocytes ≤75,000/μl.
8. Subject has a history of neoplasia with the exception of a curatively treated non-melanoma skin tumor or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years.
9. Subject has received a vaccination with a live vaccine within 12 weeks prior to the Baseline Visit (Visit 2).
10. Subject has used an investigational product or been enrolled in a clinical study including vaccines within 30 days of the Screening Visit (Visit 1).
11. Subject has known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any ingredients of the investigational product.
12. Subject is pregnant or is breastfeeding and will not abstain from breastfeeding during participation in the study and for 25 weeks post last dose of investigational product.

Primary outcomes:
measure: Incidence of AEs
timeFrame: Baseline to Week 24
measure: Incidence of Clinically Significant Changes from Baseline in Vital Signs
timeFrame: Baseline to Week 24
measure: Incidence of Clinically Significant Changes from Baseline in Clinical Laboratory Results
timeFrame: Baseline to Week 24
Secondary outcomes:
measure: Proportion of subjects who achieved absence of fever
timeFrame: Baseline to Week 24
measure: Proportion of subjects whose C-Reactive Protein (CRP) Levels Reduced by 50% or more from Baseline
timeFrame: Baseline to Week 4 and Week 12
measure: Change from Baseline in the Physician Global Assessment of Disease Activity
timeFrame: Baseline to Week 4 and Week 12
measure: Change from Baseline in the Patient Global Assessment of Disease Activity
timeFrame: Baseline to Week 4 and Week 12
measure: Change from Baseline in the modified Pouchot score
timeFrame: Baseline to Week 4 and Week 12
measure: Change from Baseline in the Disease Activity Score-28 with C-Reactive Protein (DAS28-CRP)
timeFrame: Baseline to Week 4 and Week 12
measure: Change from Baseline in CRP, ferritin, and ESR
timeFrame: Baseline to Week 4 and Week 12
measure: Serum Concentration of camoteskimab
timeFrame: Baseline through Week 24
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Sponsor Investigative Site
state: Florida
city: Ann Arbor
country: United States
facility: Sponsor Investigative Site
state: Michigan
city: Gent
country: Belgium
facility: Sponsor Investigative Site
state: Oost-Vlaanderen
city: Elbląg
country: Poland
facility: Sponsor Investigative Site
city: Pomorskie
country: Poland
facility: Sponsor Investigative Site
city: Poznań
country: Poland
facility: Sponsor Investigative Site
city: Poznań
country: Poland
facility: Sponsor Investigative Site
city: Kyiv
country: Ukraine
facility: Sponsor Investigative Site
city: Poltava
country: Ukraine
facility: Sponsor Investigative Site
city: Ternopil'
country: Ukraine
facility: Sponsor Investigative Site
city: Vinnitsa
country: Ukraine
facility: Sponsor Investigative Site
Study officials:
References: